European Primary Care Cardiovascular Society

Surprising result: Very high levels of HDL-c are associated with increased risk of CV events

Aug. 30, 2018 - Dr. Mark Philip Allard-Ratick, Atlanta, GA, USA

Association higher healthy diet score and lower risk of mortality and CV events across the globe

Aug. 28, 2018 - Dr. Andrew Mente, Hamilton, ONT, Canada

CV safety with weight loss agent in high-risk overweight or obese patients

Aug. 26, 2018 - Dr. Erin Bohula, Boston, MA, US

No overall benefit with aspirin in a primary prevention setting of diabetes patients

Aug. 27, 2018 - Prof. Jane Armitage, Oxford, UK

Omega-3 fatty acid supplements do not result in CV benefits

Aug. 26, 2018 - Dr Louise Bowman, Oxford, UK

Hypertension - Can we agree on diagnostic and therapeutic thresholds?

Mar. 16, 2018 - EPCCS 2018, Barcelona, Spain - Prof. Richard McManus, prof. Richard Hobbs and prof. Christos Lionis

Complexities of managing heart failure

Mar. 16, 2018 - EPCCS 2018, Barcelona, Spain - Dr. Clare Taylor, Dr. Nuria Farré and Dr. Frans Rutten
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (3/3)

Practical management of cardiovascular risk: Lessons from latest diabetes trials

July 17, 2018 - Prof. Lars Rydén - Stockholm, Sweden
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (2/3)

Diabetes: How to reduce risk from a cardiovascular perspective?

July 12, 2018 - Prof. Diederick Grobbee - Utrecht, The Netherlands

Lipids and food

July 11, 2018 - Prof. David Marais - Cape Town, South Africa

The cardiovascular challenge for primary care in diabetes

July 10, 2018 - Prof. Richard Hobbs - Oxford, UK

Spain - EPCCS Introduction

June 19, 2018

Lower Extremity Artery Disease: a neglected major CV disease: Diagnosis and clinical management in primary care

Mar. 15, 2018 - EPCCS 2018, Barcelona, Spain - Dr. Rafel Ramos (Girona, Spain)

Lipid lowering: the evidence, the guidelines, the clinical reality

Mar. 17, 2018 - EPCCS 2018, Barcelona, Spain - Dr. Monika Hollander, prof. Frank Visseren, dr. Jan Oltrogge

Management of CV risk that comes with T2DM in light of novel treatment options

Mar. 15, 2018 - EPCCS 2018, Barcelona, Spain - Dr. Carlos Brotons, prof. Xavier Cos, prof. Richard Hobbs

Treatment of high-risk ACS patients may change based on ODYSSEY OUTCOMES study results

Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Dr. Valentin Fuster, New York, NY, USA

Pharmacist intervention in American 'black barbershops' effective at lowering BP

Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Dr. Ronald Victor, MD - Los Angeles, CA, USA

PCSK9 inhibitor has very good benefit-to-risk profile in high risk ACS patients in ODYSSEY OUTCOMES trial

Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Prof. Gabriel Steg - Paris, France

Striking results for weight reduction in T2DM in primary care based program

Dec. 18, 2017 - IDF 2017 - Abu Dhabi, UAE - Prof Naveed Sattar, MD - Glasgow, UK

Clinical outcomes and adverse effects comparable across various BP measurement methods in SPRINT

Nov. 20, 2017 - AHA 2017 - Anaheim, CA, USA - Dr. Sripal Bangalore - NYU Langone, New York, NY, USA.

Association between GLP-1 receptor agonist therapy and decreased CV risk in T2DM patients with CKD

Oct. 18, 2018 - Mann JFE et al. - Circulation 2018

In a posthoc analysis of the LEADER trial, liraglutide treatment was associated with fewer CV outcomes in patients with type 2 diabetes and chronic kidney disease at high CV risk.

U-Prevent: a new tool to individual effect of medication on CVD

Oct. 16, 2018 - news

The UMC Utrecht's Center for Circulatory Health has developed algorithms with which the risk of CVD and the effect of medication to reduce this risk, can be predicted for every adult. Use of the risk calculators is free.

Aspirin in primary prevention: no clinical benefit for older individuals

Oct. 9, 2018 - McNeil JJ et al. - N Engl J Med 2018

The administration of low-dose aspirin had no beneficial effect for older individuals, but led to higher rates of major bleeding and all-cause mortality, compared with placebo.

New EASD-ADA consensus guidelines on managing hyperglycemia in T2DM

Oct. 9, 2018 - news

EASD 2018 Following a review of the latest evidence, the EASD and the ADA introduced new recommendations on managing hyperglycemia in T2DM, including specific drug classes for some patients and enhancing medication adherence.

Diabetes may begin more than 20 years before diagnosis

Oct. 9, 2018 - news

EASD 2018 Increased fasting glucose, higher BMI and impaired insulin sensitivity were detectable up to 10 years before the diagnosis of diabetes as well as prediabetes.

Importance increasing BMI from age 10 to adulthood in development T2DM

Oct. 3, 2018 - news

EASD 2018 Weight gain between the age of 10 and adulthood is associated with T2DM risk. Overweight children at age 10 appear to be at lower risk for developing T2DM than children who are regular weight at age 10 and then later become overweight as adults.

How quickly T2DM progresses is determined by multiple factors

Oct. 3, 2018 - news

EASD 2018 A study found various clinical and biochemical factors that are associated with a greater risk of fast disease progression in T2DM patients.

Statins only in elderly T2DM patients aged <85 years in primary prevention

Oct. 3, 2018 - Ramos R et al. - BMJ 2018

In a retrospective cohort study, statin treatment was significantly related to a reduction in the incidence of ASCVD and in all-cause mortality in elderly T2DM patients aged <85 years, which reduced after the age of 85 years and disappeared in nonagenarians.

Higher alcohol intake in young adults related to long-term adverse cardiac remodeling

Sep. 27, 2018 - Rodrigues P et al. - JACC 2018

Higher alcohol consumption in young adults was, independently of sex and race, associated with more adverse cardiac remodeling after 20 years of follow-up, as shown by a cohort study.

Long-term CV benefits with intervention for BP and cholesterol in hypertensive patients

Sep. 26, 2018 - Gupta A et al. - The Lancet 2018

BP lowering with amlodipine and lipid lowering with atorvastatin still resulted in lower rates of stroke and CV death in hypertensive patients after more than a decade, as the results of a long-term follow-up of data from the ASCOT trial show.

Diastolic BP level is important to limit CV risk, even at optimal systolic BP

Sep. 25, 2018 - Boehm M et al. - Eur Heart J 2018

In patients with a systolic BP between 120 and <140 mmHg, a diastolic BP between 70 and <80 mmHg was associated with a lower risk of adverse outcomes as compared to lower and higher DBP.

General practitioners minimally involve their patients in shared-decision making

Sep. 18, 2018 - Meijers MC et al. - Family Practice, 2018

An observational study showed longer consultations with minimal shared-decision making behavior by GPs during daily practice in 2015 compared with 2007, with less shared-decision making behavior in older patients.